Drug intelligence / Profile preview

amnion cell therapy

Development stage: Unknown
Lead developer: Monash University
Modality: Cell Therapies
Administration: Intravenous

Overview

Amnion cell therapy (I-ACT) is an investigational allogeneic cell therapy utilizing human amniotic epithelial cells (hAECs) derived from the placenta. Developed by researchers at Monash University, Monash Health, and the Hudson Institute of Medical Research, it is primarily being evaluated for the treatment of acute ischaemic stroke. The therapy is administered intravenously within 24 hours of stroke onset. Its mechanism involves neuroprotection and immunomodulation, specifically aimed at reducing infarct volume and preventing post-stroke immunosuppression. A Phase I dose-escalation trial has established the safety and feasibility of the treatment in clinical settings.

Other names: human amniotic epithelial cellshAECs

Beyond the preview

Go deeper on amnion cell therapy.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on amnion cell therapy.

Explore the full profile